A recent study published in Nature Microbiology has found that a parasite, Toxoplasma gondii, typically found in cat feces, could potentially be used as a delivery system for proteins that target neurological disorders. This parasite, which is widely known for infecting about one-third of the global population, has been genetically engineered to deliver therapeutic proteins to neurons in the brain. The study, conducted by researchers from Tel Aviv University and the University of Glasgow, injected genetically altered parasites into mice to deliver proteins into cell nuclei, showing promising results for treating neurological disorders.
The researchers found that the engineered parasite could effectively secrete MePC2, a protein linked to Rett syndrome, a neurological disorder that mainly affects women. This suggests that the parasite could be used to target other neurological disorders as well. The study authors emphasized the potential of T. gondii as a research tool due to its ability to deliver intracellular proteins to neurons, which are notoriously difficult to target with existing methods. This discovery could lead to new treatment options for conditions such as Fragile X or Duchenne Muscular Dystrophy.
Dr. Jasmin Dao, a pediatric neurologist at Miller Children’s & Women’s Hospital Long Beach, explained that T. gondii survives in human hosts by reducing the immune response and enhancing parasite proliferation. While most people infected with the parasite experience mild symptoms, those with weakened immune systems can develop severe neurological symptoms. The study results highlight the potential risks associated with using parasitic organisms like T. gondii for medical purposes, such as serious infections and behavioral alterations.
Dr. Santosh Kesari, a board-certified neurologist at Pacific Neuroscience Institute, noted that similar techniques using microorganisms have been explored for decades, with a few modified agents already FDA-approved for certain conditions. However, he cautioned that the use of engineered parasites for medical purposes is still in the early stages of research and will require further studies to optimize safety and effectiveness. Concerns include potential side effects in humans, such as inflammation and infection, which would need to be addressed in the development of such therapies.
Overall, the study’s findings suggest a promising future for using T. gondii as a delivery system for targeting neurological disorders through the delivery of therapeutic proteins to neurons in the brain. While this research is in its early stages and will require more investigation before clinical trials in humans, it offers a novel approach to treating conditions with specific protein deficiencies. With further research and development, this innovative use of a parasite could revolutionize the treatment of neurological disorders, providing new hope for patients in need of effective therapies.
